Satirical Hims & Hers Shareholder Letter - Future of Telehealth Pharmacies

TJ Parker (PillPack/Amazon Pharmacy founder)

A satirical fake shareholder letter exposing Hims & Hers business model around compounded GLP-1 medications (oral Wegovy). KEY CRITICISMS: 1. Product Efficacy Questionable - Launched without clinical data, consumer demand > science 2. Trademark Exploitation - Benefiting from Novo Nordisk brand without R&D investment 3. Zero R&D Investment - Used free liposomal tech from Utah pharmacists vs Novo B research 4. Deceptive Pricing - Anchor pricing at ,000 but no one pays that, high margins 5. Fast Follower Model - Wait for FDA approval then launch copycat without costs 6. FDA Letter = Invitation to Conversation - Treating regulatory requests as optional FUTURE IMPLICATIONS: - Traditional retail pharmacies (CVS, Walgreens) will decline - Digital-first pharmacies will dominate - Compounding will grow until regulators step in - Patient safety vs access/affordability tension continues - Whoever controls the patient relationship wins